Market Overview

Analyst Points Out Sarepta Mgmt Has Not Adjusted Outlook for Eteplirsen's Breakthrough Designation

BofA Downgrades Sarepta, But Hikes Price Target
Morning Market Losers
Healthcare ratings roundup - Upgrades/Downgrades (Seeking Alpha)

Shares of Sarepta (NASDAQ: SRPT) bounced into positive territory about an hour into Wednesday's morning session as traders responded to a Bloomberg interview with Baird's Brian Skorney.

Contrasting an earlier view from Deutsche Bank's Robyn Karnauskas, Skorney assured Sarepta has not yet changed its guidance for the breakthrough designation on eteplirsen. The analyst noted Sarepta management has said it will deciding on a strategy for eteplirsen over the next few months.

Skorney currently rates Sarpeta at Outperform with a $63 price target.

Sarepta shares have continued higher since pushing into positive territory. The stock is up more than 1.8 percent to $40.47 at last check.

Latest Ratings for SRPT

May 2015Bank of AmericaDowngradesBuyNeutral
May 2015SunTrust Robinson HumphreyUpgradesNeutralBuy
May 2015Canaccord GenuityUpgradesHoldBuy

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings


Related Articles (SRPT)

Around the Web, We're Loving...

Get Benzinga's Newsletters